Inocras Inc. – Trademark Portfolio
Entity Type: 03
Inocras Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include INOCRAS, ASDVISION, MRDVISION, RAREVISION, and RARE VISION. The owner is based in San Diego, CA.
6330 Nancy Ridge Drive, Suite 106
San Diego, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
Inocras Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Inocras Inc. have?
Inocras Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 abandoned.
What trademark classes does Inocras Inc. file in?
Inocras Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Inocras Inc.'s most well-known trademarks?
Inocras Inc.'s registered trademark portfolio includes well-known marks such as INOCRAS, ASDVISION, MRDVISION, RAREVISION, and RARE VISION. These are among 7 currently registered trademarks in the portfolio.
What is Inocras Inc.'s trademark registration success rate?
Inocras Inc. has a 88% trademark registration rate, with 7 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.